The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor

被引:164
作者
Turk, BE
Wong, TY
Schwarzenbacher, R
Jarrell, ET
Leppla, SH
Collier, RJ
Liddington, RC
Cantley, LC
机构
[1] Beth Israel Deaconess Med Ctr, Dept Med, Div Signal Transduct, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02215 USA
[3] Burnham Inst, La Jolla, CA 92037 USA
[4] NIAID, Bethesda, MD 20892 USA
[5] Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA
关键词
D O I
10.1038/nsmb708
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recent events have created an urgent need for new therapeutic strategies to treat anthrax. We have applied a mixture-based peptide library approach to rapidly determine the optimal peptide substrate for the anthrax lethal factor (LF), a metalloproteinase with an important role in the pathogenesis of the disease. Using this approach we have identified peptide analogs that inhibit the enzyme in vitro and that protect cultured macrophages from LF-mediated cytolysis. The crystal structures of LF bound to an optimized peptide substrate and to peptide-based inhibitors provide a rationale for the observed selectivity and may be exploited in the design of future generations of LF inhibitors.
引用
收藏
页码:60 / 66
页数:7
相关论文
共 43 条
[1]   Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin [J].
Agrawal, A ;
Lingappa, J ;
Leppla, SH ;
Agrawal, S ;
Jabbar, A ;
Quinn, C ;
Pulendran, B .
NATURE, 2003, 424 (6946) :329-334
[2]   THE CCP4 SUITE - PROGRAMS FOR PROTEIN CRYSTALLOGRAPHY [J].
BAILEY, S .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 1994, 50 :760-763
[3]   A novel series of matrix metalloproteinase inhibitors for the treatment of inflammatory disorders [J].
Baxter, AD ;
Bird, J ;
Bhogal, R ;
Massil, T ;
Minton, KJ ;
Montana, J ;
Owen, DA .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (07) :897-902
[4]  
Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
[5]   Crystal structure of the stromelysin catalytic domain at 2.0 Å resolution:: Inhibitor-induced conformational changes [J].
Chen, LY ;
Rydel, TJ ;
Gu, F ;
Dunaway, CM ;
Pikul, S ;
Dunham, KM ;
Barnett, BL .
JOURNAL OF MOLECULAR BIOLOGY, 1999, 293 (03) :545-557
[6]   Anthrax lethal factor proteolysis and inactivation of MAPK kinase [J].
Chopra, AP ;
Boone, SA ;
Liang, XD ;
Duesbery, NS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (11) :9402-9406
[7]   A peptide-based fluorescence resonance energy transfer assay for Bacillus anthracis lethal factor protease [J].
Cummings, RT ;
Salowe, SP ;
Cunningham, BR ;
Wiltsie, J ;
Park, YW ;
Sonatore, LM ;
Wisniewski, D ;
Douglas, CM ;
Hermes, JD ;
Scolnick, EM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (10) :6603-6606
[8]   X-ray structure of a hydroxamate inhibitor complex of stromelysin catalytic domain and its comparison with members of the zinc metalloproteinase superfamily [J].
Dhanaraj, V ;
Ye, QZ ;
Johnson, LL ;
Hupe, DJ ;
Ortwine, DF ;
Dubar, JB ;
Rubin, JR ;
Pavlovsky, A ;
Humblet, C ;
Blundell, TL .
STRUCTURE, 1996, 4 (04) :375-386
[9]   Anthrax [J].
Dixon, TC ;
Meselson, M ;
Guillemin, J ;
Hanna, PC .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (11) :815-826
[10]   Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor [J].
Duesbery, NS ;
Webb, CP ;
Leppla, SH ;
Gordon, VM ;
Klimpel, KR ;
Copeland, TD ;
Ahn, NG ;
Oskarsson, MK ;
Fukasawa, K ;
Paull, KD ;
Vande Woude, GF .
SCIENCE, 1998, 280 (5364) :734-737